| Literature DB >> 22927820 |
Irina Haecker1, Lauren A Gay, Yajie Yang, Jianhong Hu, Alison M Morse, Lauren M McIntyre, Rolf Renne.
Abstract
KSHV is the etiological agent of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and a subset of multicentricCastleman's disease (MCD). The fact that KSHV-encoded miRNAs are readily detectable in all KSHV-associated tumors suggests a potential role in viral pathogenesis and tumorigenesis. MiRNA-mediated regulation of gene expression is a complex network with each miRNA having many potential targets, and to date only few KSHV miRNA targets have been experimentally determined. A detailed understanding of KSHV miRNA functions requires high-through putribonomics to globally analyze putative miRNA targets in a cell type-specific manner. We performed Ago HITS-CLIP to identify viral and cellular miRNAs and their cognate targets in two latently KSHV-infected PEL cell lines. Ago HITS-CLIP recovered 1170 and 950 cellular KSHV miRNA targets from BCBL-1 and BC-3, respectively. Importantly, enriched clusters contained KSHV miRNA seed matches in the 3'UTRs of numerous well characterized targets, among them THBS1, BACH1, and C/EBPβ. KSHV miRNA targets were strongly enriched for genes involved in multiple pathways central for KSHV biology, such as apoptosis, cell cycle regulation, lymphocyte proliferation, and immune evasion, thus further supporting a role in KSHV pathogenesis and potentially tumorigenesis. A limited number of viral transcripts were also enriched by HITS-CLIP including vIL-6 expressed only in a subset of PEL cells during latency. Interestingly, Ago HITS-CLIP revealed extremely high levels of Ago-associated KSHV miRNAs especially in BC-3 cells where more than 70% of all miRNAs are of viral origin. This suggests that in addition to seed match-specific targeting of cellular genes, KSHV miRNAs may also function by hijacking RISCs, thereby contributing to a global de-repression of cellular gene expression due to the loss of regulation by human miRNAs. In summary, we provide an extensive list of cellular and viral miRNA targets representing an important resource to decipher KSHV miRNA function.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22927820 PMCID: PMC3426530 DOI: 10.1371/journal.ppat.1002884
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Figure 1Ago HITS-CLIP in PEL cells.
A: Western blot (WB) analysis of Argonaute immunoprecipitation with the anti-Ago antibody 2A8 [86] or an unspecific antibody (IgG) as control. The IP was blotted with the anti-Ago2 11A9 [88]. B: Autoradiogram of the radio-labeled RNA in cross-linked, immunoprecipitated Ago-miRNA-mRNA complexes after high or low RNAse treatment. Low RNase treatment yields a 110 and a 130 kDa complex. No complexes are visible with the control IgG. C: PCR products of the 1st PCR amplification step separated by urea PAGE. Linker-ligated and reverse transcribed RNA extracted from the low RNAse treatment 110 kDa complex (B, lane 3) contained predominantly miRNAs (20–25 nt+∼40 nt linkers). The 130 kDa complex contained miRNAs and 50–70 nt mRNA tags (90–110 nt including linkers). MiRNA and mRNA PCR products of the 130 kDa complex shown in lane 1 were extracted for the 2nd PCR amplification. D: products of the 2nd PCR separated on an agarose gel. The longer primers used in this PCR amplification step yielded ∼115 bp products for the miRNAs and 140–160 bp products for the mRNAs. E: Scatter plot showing the correlation of the miRNA CLIP tags between biological replicates (BR) in BCBL-1 (shown as log2 of the miRNA frequency; for reproducibility in BC-3 see Figure S1B). F: distribution of mRNA-annotated clusters across transcripts. G: differential recovery of KSHV and human miRNAs associated with Ago in BCBL-1 and BC-3.
Figure 2Ago-associated miRNA profiles in BCBL-1 and BC-3 cells.
Shown are the normalized read counts for individual miRNAs recovered from 130 kDaAgo-miRNA-mRNA complexes. Counts were normalized to the total sequencing read numbers in the sample, rescaled to 1×106 sequences (as a standard sample size) and then averaged over replicates. A: Comparison of KSHV miRNA reads in BCBL-1 and BC-3. The dashed line marks the cut-off set for the exclusion of miRNAs from targetome analysis (<200 read counts per 1×106 sequencing reads). Note that miR-K12-9 and -9* counts were above the cut-off in BCBL-1 and therefore included in the targetome analysis. B: Top 30 miRNAs sequenced from the BCBL-1 miRNA libraries, C: Top 30 miRNAs sequenced from the BC-3 miRNA libraries.
Figure 3Analysis of sequencing read clusters obtained by Ago HITS-CLIP.
mRNA libraries were analyzed for the presence of overlapping clusters of reads (super clusters) between BRs. Super cluster search was performed at two stringencies: i) super clusters present in 2 of 3 BRs (2of3), or ii) in all three BRs (3of3). The resulting super clusters were screened for miRNA seed match sites (nt 2–8) A: Cluster width distribution of super clusters containing any of the 25 (BCBL-1) or 23 (BC-3) KSHV miRNA seed matches; this analysis includes all super clusters aligning to annotated transcripts with a coverage of at least 2 copies/cluster per 106 reads. Clusters listed multiple times due to different KSHV miRNA seed matches in the same cluster were counted only once. B: Number of potential KSHV miRNA targets identified by Ago HITS-CLIP for the top18 KSHV miRNAs in BCBL-1 and the top16 in BC-3. Counted are all clusters (and corresponding number of genes) in BCBL-1 and BC-3 that passed the filtering criteria in (A) and have a cluster width of 41–300 nt. Venn diagrams show the number of unique and overlapping genes between BCBL-1 and BC-3 that are targeted by KSHV miRNAs. C: Comparison of seed match occurrence for the top18 (BCBL-1)/top16 (BC-3) KSHV miRNAs and the top30 human miRNAs in BCBL-1 and BC-3. ‘KSHV total’: all genes targeted either exclusively by KSHV miRNAs, or contain additional human miRNA seed matches; ‘KSHV only’: genes targeted exclusively by KSHV miRNAs; ‘hsa total’ and ‘hsa only’ correspondingly. Note that the number of genes targeted by KSHV miRNAs differs only slightly between BCBL-1 and BC-3 despite the strong overrepresentation of KSHV miRNAs associated with Ago in BC-3 (see Figure 1G). The number of genes targeted by human miRNAs, however, is significantly higher in BCBL-1, reflecting the much higher number (and variety) of human miRNAs associated with Ago in BCBL-1.
Figure 4Ago HITS-CLIP clusters on the viral genome.
A: Wiggle plots displaying read clusters across the KSHV genome in BCBL-1 and BC-3 cells. In contrast to BCBL-1, the KSHV genome is barely targeted in BC-3. Common targeted regions are the K2/vIL-6 gene (predominantly its 3′UTR), K5,K12/Kaposin(3′UTR), the miRNA cluster region, ORF71/vFLIP, and ORF72/vCyclin. Reads were recovered at comparable numbers from vIL-6 and K5 in both cell lines, but with a much higher coverage from the other four common loci in BC-3. In BCBL-1 several additional potential target sites were detected (K4, T1.1/PAN, ORF50/RTA, ORF58, and ORF59). Major target sites in both cell lines are marked in red, sites targeted only in BCBL-1 are marked in blue; B: prominent read cluster in the 3′UTR of K2/vIL-6 with a 6-mer miR-K12-10a target site.
Figure 5Ago-miRNA-mRNA clusters in new KSHV miRNA targets identified by Ago HITS-CLIP.
mRNA-derived clusters of reads are visualized in UCSC genome browser as wiggle tracks. Shown are the positions of read clusters overlapping with miRNA seed match sites within 3′UTRs and exons of target transcripts in BCBL-1 and BC-3. KSHV miRNA seed match positions are indicated by colored bars; those of human miRNAs as predicted by TargetScan (for 3′UTRs only) are shown as black bars. Note that in BCBL-1 the major peak of TPD52 with the two KSHV miRNA seed match sites overlaps with several smaller peaks, resulting in a total cluster width of 340 nts. Therefore, for BCBL-1, TPD52 is listed in the ‘wide cluster’ list (Table S3C).
Figure 6KSHV miRNA target validation by Luciferase Reporter Assay.
A) 3′UTR or coding sequences of new KSHV miRNA target genes suggested by Ago HITS-CLIP were cloned into a Firefly Luciferase reporter vector and co-transfected into HEK293 cells together with different amounts of the corresponding KSHV miRNA/miRNA-cluster expression vector (or the empty vector control) and a transfection control vector. Firefly signal was assayed 72 hrs post transfection (Figure S6) and normalized to the signal of the transfection control vector. Transfections were performed in triplicates. Error bars represent standard deviation of triplicates. Shown is one representative of ≥3 independent experiments. Significance of reporter vector repression at the highest miRNA expression vector dose (800 ng) compared to the empty vector control (0 ng) was tested by two-tailed, unpaired t-test. p<0.05 unless indicated (n.s.). Significance was not tested if RLU at 800 ng was higher than or equal to RLU at 0 ng. Out of 13 tested new targets 11 showed a dose-dependent repression of the Luciferase expression in the presence of the miRNA(s) that was significantly (p<0.05) different from the empty vector control. Previously validated targets BACH1 [22], [23] and C/EBPβ [24] served as positive controls. RLU = relative light units. B) For three targets, ANXA2, YWHAE, and vIL-6, the seed match site was mutated (see Figure S5 and Table S8), which, in an independent series of experiments, lead to a de-repression of the luciferase signal.
Figure 7Western blot analysis of KSHV miRNA targets.
Protein levels of two KSHV miRNA targets, TP53INP1 and YWHAE, were analyzed by Western blot in absence (0 ng) or presence (800 ng) of miR-K12-11 expression vector. Shown are two independent transfections of miR-K12-11. YWHAE showed moderate downregulation at the protein level, while TP53INP1 levels were reduced by more than 50% in the presence of miR-K12-11. Actin expression served as loading control.
Selected cellular pathways enriched in the KSHV miRNA targetome.
| Commonly targeted pathways | # genes | KSHV miRNA targets identified by Ago HITS-CLIP |
| Regulation of apoptosis | 42 | YWHAZ, APH1A, EIF5A, PRDX2, HSPA1A, HSPA1B, ITM2B, CALR, FEM1B, PTEN, IL10, RPS3, SERINC3, SQSTM1, PPP2CA, PPP2CB, RAC1, TPT1, RHOA, RPL11, HSPA5, DYRK2, TOP2A, RPS27A, ARHGDIA, HSPA9, TXNIP, IL2RB, ARHGEF2, LGALS1, PIM2, RPS6, SOD1, YWHAE, NCSTN, SON, TNFRSF10B, EIF5AL1, CFL1, HSPB1, HSPD1, APBB1, UBA52, DNM2 |
| Glycolysis | 11 | ALDOA, GPI, TPI1, LDHA, PKM2, PGAM1, HK2, PFKM, PGK1, GAPDH, MDH2 |
| protein modification by small protein conjugation or removal | 12 | COPS5, TMEM189-UBE2V1, USP9X, UBE2V1, UBE3C, OS9, RBX1, UBE2D3, HUWE1, FBXO3, RPS27A, UBA52, FBXO11 |
| protein modification by small protein conjugation | 11 | UBE2D3, TMEM189-UBE2V1, WWP2, SIAH1, UBE2V2, UBE3C, UBE2L3, RPS27A, RBX1, OS9, FBXO11 |
| antigen processing and presentation | 6 | AP3D1, HLA-C, HLA-E, CALR, HLA-G |
Enrichment was tested with all KSHV miRNA targets found at the stringency 3of3 using the Gene Ontology database DAVID [66], [67]. For complete results see Table S7.